ONE-SITE-STOP
LIVE

Serial Number

79295861

Owner

Hovione Scientia Limited

Attorney

R. Peter Spies

Filing Date

Jun 2, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ONE-SITE-STOP Trademark

Serial Number: 79295861 • Registration: 6655646

ONE-SITE-STOP is a trademark filed by Hovione Scientia Limited on June 2, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Hovione Scientia Limited (16 trademarks)

Loughbeg

Entity Type: 99

Trademark Details

Filing Date

June 2, 2020

Registration Date

March 1, 2022

Published for Opposition

December 14, 2021

Goods & Services

Compositions for medical and veterinarian use, namely, chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; diagnostic preparations for medical purposes; chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals

Active chemical ingredients for use in the manufacture of pharmaceuticals for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals

Development of pharmaceutical products and drug products; research on pharmaceutical products and drug products; research and development of new products in the pharmaceutical industry; consulting services in the field of design and development of engineering processes for the pharmaceutical industry; research and development services in the pharmaceutical field; research and development services in the field of pharmaceuticals, chemical preparations, vaccines, medicines, antibodies, new products in the medical field

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 26, 2025 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Sep 18, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 22, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 3, 2022 FICS
FINAL DISPOSITION PROCESSED
Aug 3, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 1, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 1, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Dec 19, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 14, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 14, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 24, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 24, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 24, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 9, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 9, 2021 CRFA
ASSIGNED TO LIE
Nov 9, 2021 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 4, 2021 ERFR
EXAMINER'S AMENDMENT ENTERED
Nov 4, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 4, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 4, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 4, 2021 CNEA
NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2021 NREP
NOTIFICATION OF FINAL REFUSAL EMAILED
May 13, 2021 GNFN
FINAL REFUSAL E-MAILED
May 13, 2021 GNFR
FINAL REFUSAL WRITTEN
May 13, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 4, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 4, 2021 TROA
REFUSAL PROCESSED BY IB
Nov 29, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 10, 2020 RFCS
REFUSAL PROCESSED BY MPU
Nov 10, 2020 RFRR
APPLICATION FILING RECEIPT MAILED
Oct 23, 2020 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 21, 2020 RFCR
NON-FINAL ACTION WRITTEN
Oct 20, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 19, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 19, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 15, 2020 REPR